Tidal Investments LLC Increases Stake in Illumina, Inc. $ILMN

Tidal Investments LLC raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 10.3% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 93,728 shares of the life sciences company’s stock after acquiring an additional 8,726 shares during the period. Tidal Investments LLC’s holdings in Illumina were worth $16,480,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. MCF Advisors LLC boosted its stake in shares of Illumina by 172.4% during the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 100 shares during the period. National Pension Service raised its holdings in Illumina by 246.7% during the 2nd quarter. National Pension Service now owns 369,856 shares of the life sciences company’s stock valued at $65,032,000 after buying an additional 263,172 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in Illumina during the 2nd quarter valued at $6,041,000. NewEdge Advisors LLC grew its holdings in Illumina by 8.6% in the 2nd quarter. NewEdge Advisors LLC now owns 4,740 shares of the life sciences company’s stock worth $833,000 after acquiring an additional 377 shares during the last quarter. Finally, IFP Advisors Inc increased its position in shares of Illumina by 43.7% in the second quarter. IFP Advisors Inc now owns 1,930 shares of the life sciences company’s stock valued at $339,000 after acquiring an additional 587 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

ILMN stock opened at $201.27 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $231.81. The firm has a 50-day moving average of $200.54 and a 200 day moving average of $161.87. The company has a market cap of $30.39 billion, a P/E ratio of 37.55, a PEG ratio of 2.90 and a beta of 1.46.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. During the same period in the previous year, the firm posted $1.19 EPS. The business’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts forecast that Illumina, Inc. will post 5.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ILMN. Argus increased their target price on shares of Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. Zacks Research cut Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 1st. Stifel Nicolaus lifted their price objective on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Piper Sandler reissued an “overweight” rating and set a $225.00 target price (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Illumina in a report on Monday, August 31st. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $199.12.

Insider Activity at Illumina

In related news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the sale, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders sold 2,062,465 shares of company stock valued at $436,589,802. Company insiders own 2.90% of the company’s stock.

About Illumina

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company’s sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.